本帖最后由 老马 于 2012-1-13 21:20 编辑
, A2 i5 z1 K+ q% X* z+ [. N
) E, @* D" ^2 A+ m/ U3 X爱必妥和阿瓦斯丁的比较$ w5 V8 k2 [- R$ \5 E- L
# F" ]3 |% L0 q7 k% m0 ]+ a1 u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; G8 c2 m% ^- \* B3 ~
9 v! l( I8 \ z# r2 J& N {' s
8 `$ [9 k$ e7 `( v& \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ q! @+ i5 ]' l5 ?# O0 I
==================================================1 i0 T6 A; V8 @ D! }& v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ]' q7 G. n: f0 e& H& |. m1 L( s
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. d0 ?- C# ]7 I" ZResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' h- I5 G* e3 ^, m# l4 Q$ d$ [
|